While this is a big goal we think it is one that is achievable. We believe our products are very attractive alternatives to the current therapies that are on the market today -- aspirin, Tylenol and Ibuprofen are simply not always effective and there certainly are side effects with these medications. As most everyone knows, medications such as Vioxx and Celebrex been removed from the market, except in very limited cases. These drugs, which were initially billed as virtual miracle cures turned out to be anything but miracles and, of course, the heavy-duty drugs such as Vicodin, are simply not an alternative for the vast majority of people.
We believe this situation leaves us with a huge hole in the healthcare industry relating to pain relief. We sincerely believe that ActiPatch can fill that hole and fit somewhere between the use of aspirin, Tylenol and Ibuprofen and the heavy-duty drugs that very few people should be taking. We believe we are already achieving this goal outside of the United States and as we do additional clinical trials in the United States we hope to eventually also achieve this domestically.
Price of BioElectronics Shares -- It is difficult, of course, for us to
directly comment on the valuation of our stock. We believe the current
stock price is based on a lot of old information. It has taken a while for
BioElectronics to get off the ground relative to sales and the sales ramp
is in fact happening very significantly at the current moment. We simply
cannot imagine the stock price staying anywhere near the current levels as
the information that we provided today moves in to the general shareh
|SOURCE BioElectronics Corporation|
Copyright©2008 PR Newswire.
All rights reserved